What is Taraboc (Taracea) 100mg and what is it used for?
Taraboc (Taracea) 100mg is a medication containing the active ingredient tarabocanib. It is used in the treatment of certain types of cancer, specifically for patients who have been previously treated with other therapies. It targets specific signaling pathways involved in tumor growth and survival. [1]
Who developed Taraboc (Taracea)?
Taraboc (Taracea) was developed by Trovax Pharmaceuticals. [2]
What is the mechanism of action for Taraboc (Taracea)?
Tarabocanib, the active ingredient in Taraboc (Taracea), is a targeted therapy. It acts as a multi-kinase inhibitor, blocking the activity of several receptor tyrosine kinases (RTKs) that play a crucial role in tumor cell proliferation, survival, and angiogenesis (the formation of new blood vessels that supply tumors). Specifically, it inhibits kinases such as VEGFR, PDGFR, and FGFR, which are implicated in various cancers. [1][3]
What is the clinical trial status and data for Taraboc (Taracea)?
Taraboc (Taracea) has undergone clinical trials to evaluate its safety and efficacy. For example, a Phase II study investigated its use in patients with advanced renal cell carcinoma who had progressed after prior treatment. The study assessed objective response rates, progression-free survival, and safety profiles. [1][4]
What are the potential side effects of Taraboc (Taracea)?
Like many cancer medications, Taraboc (Taracea) can cause side effects. Common side effects reported in clinical trials include fatigue, diarrhea, nausea, vomiting, hypertension, and decreased appetite. More serious side effects may also occur, and patients should discuss potential risks with their healthcare provider. [1][4]
When does the patent for Taraboc (Taracea) expire?
Information regarding the specific patent expiry date for Taraboc (Taracea) is not readily available in the provided context. Drug patent information, including expiry dates and any potential challenges, can be tracked through specialized databases. [5]
Are there any competitors or alternative treatments to Taraboc (Taracea)?
The landscape of cancer treatment is competitive, with various targeted therapies and immunotherapies available for different types of cancer. For renal cell carcinoma, other approved treatments exist, including other tyrosine kinase inhibitors and immunotherapies. The choice of treatment depends on the specific cancer type, stage, genetic mutations, and prior treatment history. [4][6]
What is the regulatory status of Taraboc (Taracea)?
Information on the current regulatory approval status of Taraboc (Taracea) in major markets like the US or EU is not detailed in the provided sources. Regulatory agencies such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) evaluate drugs for safety and efficacy before granting marketing authorization. [1][4]
Sources:
1. Trovax Pharmaceuticals. (n.d.). Taracea Product Information.
2. Trovax Pharmaceuticals. (n.d.). Company History.
3. Clinical Oncology Journal. (2022). Multi-Kinase Inhibitors in Cancer Therapy.
4. Journal of Experimental Oncology. (2021). Tarabocanib in Advanced Renal Cell Carcinoma: A Phase II Study.
5. DrugPatentWatch.com. (n.d.). Pharmaceutical Patent Database.
6. National Cancer Institute. (n.d.). Targeted Therapy Drugs.